Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Delcath Systems, Inc. (DCTH)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
10.06-0.05 (-0.49%)
At close: 4:00PM EDT
10.06 0.00 (0.00%)
After hours: 04:00PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Inside Bar (Bearish)

Inside Bar (Bearish)

Previous Close10.11
Open10.30
Bid9.83 x 1800
Ask11.28 x 900
Day's Range9.81 - 10.70
52 Week Range8.28 - 25.18
Volume37,983
Avg. Volume28,945
Market Cap74.004M
Beta (5Y Monthly)0.44
PE Ratio (TTM)N/A
EPS (TTM)-4.49
Earnings DateNov 09, 2021 - Nov 15, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est22.75
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for DCTH

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Delcath Systems, Inc.
    PETS: What does Argus have to say about PETS?PETMED EXPRESS INC has an Investment Rating of HOLD; a target price of $28.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
    Rating
    Fair Value
    Economic Moat
    11 days agoArgus Research
View more
  • GlobeNewswire

    Delcath Systems to Present at Upcoming Virtual Investor Conferences

    NEW YORK, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will participate in three upcoming conferences: H.C. Wainwright 23rd Annual Global Investment Conference: September 13th to 15th, 2021 Presentation Date and Time: On-demand beginning 9/13/2021 at 7:00 AM (ET)Webcast: https://journey.ct.events/view/ee8971f7-2bcf-428c-91e5-3ff7d70376abManage

  • GlobeNewswire

    Delcath Systems Announces Second Quarter 2021 Results

    NEW YORK, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, today reported business highlights and financial results for the second quarter ended June 30, 2021. Recent Business Highlights During and since the second quarter the company: Had positive efficacy results presented from its FOCUS Phase III trial of HEPZATO™ KIT (melphalan hydrochloride for injection/he

  • GlobeNewswire

    Delcath Systems Secures Up to a $20.0 Million Debt Facility with Avenue Venture Opportunities Fund, L.P.

    NEW YORK, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today that it has entered into a debt facility with Avenue Venture Opportunities Fund, L.P. ("Avenue Venture Fund") providing up to $20 million with an initial $15 million funded at close. Additional details concerning the debt facility will be contained in the company's Current Report on Form

Advertisement
Advertisement